GRAIL INC (GRAL) Stock Price & Overview
NASDAQ:GRAL • US3847471014
Current stock price
The current stock price of GRAL is 49.13 USD. Today GRAL is up by 4.89%. In the past month the price increased by 14.18%. In the past year, price increased by 82.44%.
GRAL Key Statistics
- Market Cap
- 2.015B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -11.17
- Dividend Yield
- N/A
GRAL Stock Performance
GRAL Stock Chart
GRAL Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to GRAL. When comparing the yearly performance of all stocks, GRAL is one of the better performing stocks in the market, outperforming 80.64% of all stocks.
GRAL Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to GRAL. While GRAL has a great health rating, there are worries on its profitability.
GRAL Earnings
On February 19, 2026 GRAL reported an EPS of -2.44 and a revenue of 43.60M. The company beat EPS expectations (11.6% surprise) and missed revenue expectations (-2.15% surprise).
GRAL Forecast & Estimates
12 analysts have analysed GRAL and the average price target is 95.06 USD. This implies a price increase of 93.49% is expected in the next year compared to the current price of 49.13.
For the next year, analysts expect an EPS growth of -0.16% and a revenue growth 23.93% for GRAL
GRAL Groups
Sector & Classification
GRAL Financial Highlights
Over the last trailing twelve months GRAL reported a non-GAAP Earnings per Share(EPS) of -11.17. The EPS increased by 83.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.97% | ||
| ROE | -15.84% | ||
| Debt/Equity | 0 |
GRAL Ownership
GRAL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.81 | 362.599B | ||
| AMGN | AMGEN INC | 15.32 | 187.489B | ||
| GILD | GILEAD SCIENCES INC | 15.54 | 170.335B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.28 | 115.33B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.75 | 77.479B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 41.1 | 41.4B | ||
| INSM | INSMED INC | N/A | 29.315B | ||
| NTRA | NATERA INC | N/A | 27.677B | ||
| BIIB | BIOGEN INC | 11.42 | 26.631B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.45 | 22.979B | ||
| MRNA | MODERNA INC | N/A | 20.292B | ||
| EXAS | EXACT SCIENCES CORP | 345.14 | 20.026B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.981B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GRAL
Company Profile
GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. The company is headquartered in Menlo Park, California and currently employs 910 full-time employees. The company went IPO on 2024-06-12. The firm is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
Company Info
IPO: 2024-06-12
GRAIL INC
1525 O'brien Drive
Menlo Park CALIFORNIA US
Employees: 910
Phone: 13026587581
GRAIL INC / GRAL FAQ
Can you describe the business of GRAIL INC?
GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. The company is headquartered in Menlo Park, California and currently employs 910 full-time employees. The company went IPO on 2024-06-12. The firm is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
Can you provide the latest stock price for GRAIL INC?
The current stock price of GRAL is 49.13 USD. The price increased by 4.89% in the last trading session.
Does GRAIL INC pay dividends?
GRAL does not pay a dividend.
What is the ChartMill technical and fundamental rating of GRAL stock?
GRAL has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
On which exchange is GRAL stock listed?
GRAL stock is listed on the Nasdaq exchange.
What is GRAIL INC worth?
GRAIL INC (GRAL) has a market capitalization of 2.02B USD. This makes GRAL a Mid Cap stock.
Can you provide the ownership details for GRAL stock?
You can find the ownership structure of GRAIL INC (GRAL) on the Ownership tab.